Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6192891 | Journal of Thoracic Oncology | 2015 | 14 Pages |
Abstract
Our results imply that EGFR-TKIs could not only directly inhibit tumor cell viability but also indirectly enhance antitumor immunity through the downregulation of PD-L1. Anti-PD-1/PD-L1 antibodies could be an optional therapy for EGFR-TKI sensitive patients, especially for EGFR-TKIs resistant NSCLC patients with EGFR mutation. Combination of EGFR-TKIs and anti-PD-1/PD-L1 antibodies treatment in NSCLC is not supported by the current study but warrant more studies to move into clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nan MD, Wenfeng MD, PhD, Jianhua MD, Shaodong MD, Yanna MD, Shiyang MD, Yaxiong MD, Xiaobo MD, Ting MD, Tao MD, Yan MD, PhD, Xianping MD, PhD, Li MD,